Details
Stereochemistry | MIXED |
Molecular Formula | C12H13NO3S3 |
Molecular Weight | 315.432 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(SC(=O)C1=CC=CS1)C(=O)NC2CCSC2=O
InChI
InChIKey=MKTVMEMIKNBVHI-UHFFFAOYSA-N
InChI=1S/C12H13NO3S3/c1-7(19-12(16)9-3-2-5-17-9)10(14)13-8-4-6-18-11(8)15/h2-3,5,7-8H,4,6H2,1H3,(H,13,14)
Molecular Formula | C12H13NO3S3 |
Molecular Weight | 315.432 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Midesteine (previously known as MR 889), a thiolactic acid derivative was developed as an inhibitor of the chymotrypsin and elastolytic activity of leukocyte elastase. Midesteine participated in clinical trials for patients with chronic obstructive pulmonary disease. The drug is also studied to treat asthma, cystic fibrosis, and emphysema. However, all these studies were discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
The kinetic mechanism of inhibition of human leukocyte elastase by MR889, a new cyclic thiolic compound. | 1990 Mar 1 |
|
MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. | 1996 Jul |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8836663
Thirty subjects were administered MR889 orally at a dose of 500 mg b.i.d. for 4 weeks, and 30 received placebo following the same schedule.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:54:22 UTC 2023
by
admin
on
Fri Dec 15 18:54:22 UTC 2023
|
Record UNII |
90K2YE9FTO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1808549
Created by
admin on Fri Dec 15 18:54:22 UTC 2023 , Edited by admin on Fri Dec 15 18:54:22 UTC 2023
|
PRIMARY | |||
|
C062051
Created by
admin on Fri Dec 15 18:54:22 UTC 2023 , Edited by admin on Fri Dec 15 18:54:22 UTC 2023
|
PRIMARY | |||
|
6572
Created by
admin on Fri Dec 15 18:54:22 UTC 2023 , Edited by admin on Fri Dec 15 18:54:22 UTC 2023
|
PRIMARY | |||
|
94149-41-4
Created by
admin on Fri Dec 15 18:54:22 UTC 2023 , Edited by admin on Fri Dec 15 18:54:22 UTC 2023
|
PRIMARY | |||
|
SUB08953MIG
Created by
admin on Fri Dec 15 18:54:22 UTC 2023 , Edited by admin on Fri Dec 15 18:54:22 UTC 2023
|
PRIMARY | |||
|
90K2YE9FTO
Created by
admin on Fri Dec 15 18:54:22 UTC 2023 , Edited by admin on Fri Dec 15 18:54:22 UTC 2023
|
PRIMARY | |||
|
100000080608
Created by
admin on Fri Dec 15 18:54:22 UTC 2023 , Edited by admin on Fri Dec 15 18:54:22 UTC 2023
|
PRIMARY | |||
|
C175137
Created by
admin on Fri Dec 15 18:54:22 UTC 2023 , Edited by admin on Fri Dec 15 18:54:22 UTC 2023
|
PRIMARY | |||
|
65837
Created by
admin on Fri Dec 15 18:54:22 UTC 2023 , Edited by admin on Fri Dec 15 18:54:22 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|